Anti-inflammatory effects of propofol are mediated by apolipoprotein M in a hepatocyte nuclear factor-1α-dependent...

Area of Science:

• Pharmacology and Immunology
• Molecular Mechanisms of Inflammation

Background:

• Propofol (2,6-diisopropylphenol) is a widely used intravenous hypnotic agent.
• The anti-inflammatory properties of propofol remain largely unaddressed in clinical practice.
• Systemic inflammatory response syndrome (SIRS) involves complex inflammatory pathways.

Purpose of the Study:

• To evaluate the anti-inflammatory activity and underlying mechanisms of propofol.
• To investigate propofol's effects on lipopolysaccharide (LPS)-induced inflammation in vitro and in vivo.
• To elucidate the role of hepatocyte nuclear factor-1α (HNF-1α) and apolipoprotein M (APOM) in propofol's anti-inflammatory action.

Main Methods:

• Assessed propofol's impact on LPS-induced pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) and iNOS expression.
• Utilized in vivo and in vitro models of LPS-induced inflammation.
• Investigated the expression levels of HNF-1α and APOM following propofol and LPS treatment, including siRNA-mediated knockdown experiments.

Main Results:

• Propofol significantly inhibited LPS-induced production of pro-inflammatory cytokines and iNOS expression.
• LPS treatment down-regulated HNF-1α and APOM expression, which was compensated by propofol.
• Propofol's anti-inflammatory effect was dependent on APOM, suggesting a pathway where propofol up-regulates APOM via HNF-1α to reduce inflammation.

Conclusions:

• Propofol exhibits significant anti-inflammatory properties by modulating key molecular pathways.
• The mechanism involves propofol enhancing HNF-1α expression, leading to increased APOM, which subsequently suppresses pro-inflammatory cytokine production.
• These findings offer insights into propofol's potential therapeutic role in managing SIRS.